SPOTLIGHT -
EP. 1: Diagnosis of Myelodysplastic Syndrome
EP. 2: Clinical Presentation and Symptoms of MDS
EP. 3: Risk Stratification in MDS
EP. 4: The Use of Molecular Testing in MDS
EP. 5: Factoring in Comorbidities in MDS Risk Stratification
EP. 6: Re-Staging Patients with MDS
EP. 7: Thresholds for Blood Transfusions for MDS
EP. 8: Iron Chelation Therapy for MDS
EP. 9: MDS: Low-Risk Disease Treatment Options
EP. 10: Erythropoiesis-Stimulating Agents for Lower-Risk MDS
EP. 11: Lenalidomide in Del 5q MDS
EP. 12: Phase III MEDALIST Trial of Luspatercept for MDS
EP. 13: Emerging Agents in Development for MDS
EP. 14: Final Thoughts From ASH 2019 on MDS
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
